Zydus launches Rexigo, oral once-a-day pill to treat advanced prostate cancer EP News Bureau Jan 30, 2024 Relugolix is reportedly the only oral option of ADT drugs known as gonadotropin releasing hormone (GnRH) analogues
Myovant Sciences and Accord Healthcare enter into exclusive licence agreement to commercialise… EP News Bureau May 13, 2022 Myovant to receive an upfront payment of $50 million, is eligible to receive commercial launch, sales-based and other milestones…
